Literature DB >> 16987999

Action of epoxyeicosatrienoic acids on cellular function.

Arthur A Spector1, Andrew W Norris.   

Abstract

Epoxyeicosatrienoic acids (EETs), which function primarily as autocrine and paracrine mediators in the cardiovascular and renal systems, are synthesized from arachidonic acid by cytochrome P-450 epoxygenases. They activate smooth muscle large-conductance Ca(2+)-activated K(+) channels, producing hyperpolarization and vasorelaxation. EETs also have anti-inflammatory effects in the vasculature and kidney, stimulate angiogenesis, and have mitogenic effects in the kidney. Many of the functional effects of EETs occur through activation of signal transduction pathways and modulation of gene expression, events probably initiated by binding to a putative cell surface EET receptor. However, EETs are rapidly taken up by cells and are incorporated into and released from phospholipids, suggesting that some functional effects may occur through a direct interaction between the EET and an intracellular effector system. In this regard, EETs and several of their metabolites activate peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma, suggesting that some functional effects may result from PPAR activation. EETs are metabolized primarily by conversion to dihydroxyeicosatrienoic acids (DHETs), a reaction catalyzed by soluble epoxide hydrolase (sEH). Many potentially beneficial actions of EETs are attenuated upon conversion to DHETs, which do not appear to be essential under routine conditions. Therefore, sEH is considered a potential therapeutic target for enhancing the beneficial functions of EETs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987999     DOI: 10.1152/ajpcell.00402.2006

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  205 in total

1.  The protective effect of epoxyeicosatrienoic acids on cerebral ischemia/reperfusion injury is associated with PI3K/Akt pathway and ATP-sensitive potassium channels.

Authors:  You-Yang Qu; Mei-Yan Yuan; Yu Liu; Xing-Jun Xiao; Yu-Lan Zhu
Journal:  Neurochem Res       Date:  2014-11-04       Impact factor: 3.996

2.  Soluble epoxide hydrolase as an anti-inflammatory target of the thrombolytic stroke drug SMTP-7.

Authors:  Naoki Matsumoto; Eriko Suzuki; Makoto Ishikawa; Takumi Shirafuji; Keiji Hasumi
Journal:  J Biol Chem       Date:  2014-10-31       Impact factor: 5.157

3.  Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.

Authors:  Ahmet B Inceoglu; Heather L Clifton; Jun Yang; Christine Hegedus; Bruce D Hammock; Saul Schaefer
Journal:  J Cardiovasc Pharmacol       Date:  2012-07       Impact factor: 3.105

4.  11,12,20-Trihydroxy-eicosa-8(Z)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries.

Authors:  Ishfaq A Bukhari; Abdul Jabbar Shah; Kathryn M Gauthier; Katherine A Walsh; Sreenivasulu Reddy Koduru; John D Imig; John R Falck; William B Campbell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 5.  Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism.

Authors:  Arthur A Spector; Hee-Yong Kim
Journal:  Biochim Biophys Acta       Date:  2014-08-02

Review 6.  The 2014 Bernard B. Brodie award lecture-epoxide hydrolases: drug metabolism to therapeutics for chronic pain.

Authors:  Sean D Kodani; Bruce D Hammock
Journal:  Drug Metab Dispos       Date:  2015-03-11       Impact factor: 3.922

7.  Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke.

Authors:  Jafar Sadik B Shaik; Muzamil Ahmad; Wenjin Li; Marie E Rose; Lesley M Foley; T Kevin Hitchens; Steven H Graham; Sung Hee Hwang; Bruce D Hammock; Samuel M Poloyac
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-09-16       Impact factor: 4.733

Review 8.  Arachidonic acid cytochrome P450 epoxygenase pathway.

Authors:  Arthur A Spector
Journal:  J Lipid Res       Date:  2008-10-23       Impact factor: 5.922

9.  Cif is negatively regulated by the TetR family repressor CifR.

Authors:  Daniel P MacEachran; Bruce A Stanton; George A O'Toole
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

10.  Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Authors:  Kimberly L Fife; Yingmei Liu; Kara R Schmelzer; Hsing-Ju Tsai; In-Hae Kim; Christophe Morisseau; Bruce D Hammock; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-09-24       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.